Immune-Onc Therapeutics Announces $ 73 Million Series B1 and B2 Funding to Advance its Portfolio of New Immunotherapies Against Blood Cancers and Solid Tumors

PALO ALTO, Calif .– (COMMERCIAL THREAD) – Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing new biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced the closing of ” Series B1 and B2 financing of $ 73 million. The round was led by Oceanpine Capital with the participation of additional …

Read More »

Fourth Quarter Profits Rise

Officials from First Horizon Corp. expect an economic rebound in the Southeast later this summer, as more people receive the COVID-19 vaccine. Memphis-based First Horizon said on Friday that its quarterly profits nearly doubled to $ 234 million. The bank merged in the third quarter with IberiaBank Corp. of Lafayette, …

Read More »